Shares of the Australian speciality pharmaceutical company Acrux (ASX:ACR) rose as much as 4.9% to A$0.043, an increase that marks their highest intraday percent gain since September 6.

Acrux (ASX:ACR) reached its peak since September 12.

The company has announced the termination of the commercialisation deal of the generic Testosterone Topical Solution product for the U.S.

market.

Following this termination, Acrux (ASX:ACR) will maintain exclusive ownership of all rights and intellectual property of the product.

Despite this uptick, the stock is down 41.4% this year, as of the last close, compared to a 2.2% increase in the benchmark S&P/ASX 200 index.

Acrux (ASX:ACR) is an Australian speciality pharmaceutical company focused on developing and commercializing a range of patient-preferred pharmaceutical products.